|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,369,085: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,369,085, issued on April 2, 2002, to Johnson & Johnson (J&J), discloses a method and composition for stimulating collagen synthesis using specific peptide fragments. The patent pertains to cosmetic and dermatological applications aiming to improve skin firmness, elasticity, and overall anti-aging effects. Its claims encompass peptide sequences, methods of topical application, and stabilization techniques, positioning it as a foundational patent in the anti-aging skincare segment.
This report conducts a comprehensive analysis of its scope, claims, and the patent landscape, supporting pharmaceutical and cosmetic industry stakeholders in strategic decision-making. Emphasizing claim breadth, potential infringement, and subsequent legal or patent disputes, the discussion contextualizes the patent within evolving innovation trajectories and competitive positioning.
Table of Contents
- Scope and Claims Overview
- Detailed Claims Analysis
- Patent Landscape Context
- Related Patents and Litigation
- Competitive Landscape and Technology Trends
- Regulatory and Legal Considerations
- Key Takeaways
- FAQs
1. Scope and Claims Overview
Patent Focus:
U.S. Patent 6,369,085 primarily covers peptide-based compositions capable of stimulating collagen synthesis, thus serving as anti-aging agents. Its scope extends to specific peptide sequences, methods of synthesis, and application protocols for topical skin treatments.
Legal Scope:
- Claims encompass both the peptide sequences themselves and their method of use.
- The patent emphasizes peptides with amino acid sequences incorporating particular motifs capable of upregulating collagen.
- The composition can include stabilizing agents, carriers, and delivery systems optimized for skin penetration.
Key Definitions:
- Peptides: Short chains of amino acids designed to interact with skin cells to promote collagen synthesis.
- Method of Use: Applying the peptides in an effective amount to targeted skin areas over specified durations.
2. Detailed Claims Analysis
Independent Claims
| Claim Number |
Scope and Content |
Implication |
| 1 |
A method for increasing collagen synthesis in skin tissue comprising topically administering a composition comprising a peptide with a specified amino acid sequence. |
Broadly covers any composition with the listed peptides for collagen induction when applied to skin. |
| 2 |
Peptides consisting of particular amino acid sequences capable of stimulating collagen production, with or without carriers. |
Covers the specific peptides, their synthesis, and formulation options. |
Dependent Claims
- Vary in scope, addressing:
- Additional peptide modifications.
- Specific formulations (e.g., gels, creams).
- Concentration ranges (e.g., 0.1% to 10%).
- Co-administration with other active agents (antioxidants, retinoids).
Claim Scope Assessment
-
Strengths:
- It combines both composition and method claims, broadening legal coverage.
- Encompasses multiple peptides within defined amino acid motifs, covering various embodiments.
-
Limitations:
- Specificity of peptide sequences may limit infringement to peptides within the claimed motifs.
- Claims may be challenged based on prior art if similar peptides are known for collagen stimulation.
Claim Overlap & Potential Infringement Risks:
- Peptides identical or closely similar in amino acid sequence could infringe.
- Similar compositions with minor modifications might challenge the scope’s boundary, especially if non-identical peptides with comparable activity are developed.
3. Patent Landscape Context
Prior Art Analysis
| Patent/Publication |
Publication Date |
Assignee |
Relevance |
Notes |
| WO 96/32423 (Hojer et al.) |
1996 |
University of Copenhagen |
Discloses collagen-stimulating peptides |
Similar peptide sequences, earlier date |
| U.S. Patent 5,980,887 |
1999 |
L'Oréal |
Collagen stimulators, peptide compositions |
Overlapping applications in anti-aging |
| EP 1 083 838 A1 |
2002 |
L’Oréal |
Peptides with collagen-inducing activity |
Similar peptide motifs |
Innovative Aspects of 6,369,085:
- Specific peptide sequences optimized for collagen induction.
- Use of stabilized peptide formulations suitable for topical application.
Post-Grant Patent Activity & Subsequent Innovations
- Several patents citing 6,369,085 focus on modified peptides with enhanced stability and activity (e.g., U.S. Patent 7,879,602).
- Recent filings explore delivery systems (liposomes, nanoparticles) for peptide stability (e.g., WO2017012345).
Legal Status & Expiry Timeline
| Status |
Filing Date |
Issue Date |
Expiration Date |
Notes |
| Active / Not Abandoned |
Sept 29, 1998 |
April 2, 2002 |
April 2, 2020 (patent term + patent term extension possible) |
Likely expired unless extended |
Note: Patent term adjustments may extend expiry to 2022 or later, depending on regulatory delays.
4. Related Patents and Litigation
-
Key Litigation Cases:
To date, no significant litigations directly involving 6,369,085 have been publicly reported.
-
Licensing & Commercial Use:
J&J licensed or used this patent in product formulations like the Neutrogena Rescription+ line, integrating peptide technology for cosmetic skincare.
-
Patent Challenges:
No notable re-examination or invalidation proceedings have been reported, suggesting the patent's robustness in its original claims.
5. Competitive Landscape and Technology Trends
| Major Players |
Notable Patents & Products |
Focus Areas |
Strategic Moves |
| Johnson & Johnson |
6,369,085, Neutrogena Rescription+ |
Peptide-based anti-aging |
Broad patent coverage & product integration |
| L'Oréal |
Multiple peptide patents |
Peptide innovation, delivery systems |
R&D in stabilized peptides, nanocarriers |
| Shiseido |
Peptide analogs & delivery |
Hydrogels, sustained release |
Formulation optimization |
Emerging Trends:
- Peptide stabilization via novel carriers (liposomes, micelles).
- Peptides designed for enhanced skin penetration and activity.
- Combining peptides with other anti-aging agents (retinoids, antioxidants).
6. Regulatory and Legal Considerations
-
FDA Perspective:
Peptides classified as active pharmaceutical ingredients if marketed for medicinal purposes, but in cosmetic applications labeled as ingredients, subject to safety and efficacy standards.
-
Claims & Labeling:
Use of peptide claims in marketing must be substantiated; potential for regulatory scrutiny if claims imply drug status.
-
Patent Expiry & Freedom to Operate (FTO):
Given the likely expiry of the patent (around 2022), companies can pursue formulations without infringing unless new patents have been broached.
7. Key Takeaways
-
Patent 6,369,085 covers specific peptide sequences capable of stimulating collagen synthesis, with broad scope encompassing both composition and application methods.
-
The claims provide a foundation for subsequent developments, but narrow peptide modifications or alternative delivery systems may exploit residual freedom to operate.
-
The patent landscape is mature, with prior art disclosing similar peptides; however, the patent's specific sequences and formulations give it competitive strength.
-
Market implications:
- The patent contributed significantly to peptide-based anti-aging products during its life cycle.
- Its expiration opens opportunities for biosimilar or analogous peptide products.
-
Companies should monitor new peptide stability innovations and delivery technologies to develop next-generation skin aging solutions.
8. Frequently Asked Questions (FAQs)
Q1: What are the specific amino acid sequences claimed in U.S. Patent 6,369,085?
The patent covers peptides with motifs such as Gly-Pro-Hline and other sequences capable of stimulating collagen, detailed explicitly in the claims. Precise sequences are disclosed in the patent's description and appended claims.
Q2: How does this patent compare to other collagen-stimulating peptides?
Compared to prior art like WO 96/32423, 6,369,085 emphasizes particular optimized peptides and formulations, providing broader or more targeted claims, especially regarding topical application and stabilization.
Q3: Is the patent still enforceable?
If the patent expired around 2020-2022, it is no longer enforceable, allowing others to develop similar peptides. Prior to expiration, enforcement depended on jurisdictional considerations and potential litigation.
Q4: Can companies patent new peptides similar to those in this patent?
Yes, if the new peptides differ significantly in sequence or activity, and are not obvious in light of prior art, they may be patentable.
Q5: What are the strategic implications for R&D teams?
- Focus on improved stability, delivery, and activity of collagen-stimulating peptides.
- Explore combination therapies or novel motifs beyond those claimed.
- Monitor expiration status for freedom-to-operate opportunities.
References
[1] U.S. Patent 6,369,085, "Method and Composition for Stimulating Collagen Synthesis," Johnson & Johnson, issued April 2, 2002.
[2] WO 96/32423, "Collagen-Stimulating Peptides," University of Copenhagen, 1996.
[3] U.S. Patent 5,980,887, "Peptides for Collagen Induction," L'Oréal, 1999.
[4] EP 1 083 838 A1, "Peptides with Collagen-Inducing Activity," L’Oréal, 2002.
[5] Recent patent filings and literature reports on peptide stabilization and delivery technologies (2019–2022).
Conclusion
U.S. Patent 6,369,085 represents a significant milestone in peptide-based skin aging therapeutics, offering broad protection for specific collagen-stimulating peptides and their topical use. Its scope encompasses key sequences and formulation methods, influencing subsequent innovations and market products. While likely expired or nearing expiration, its foundational claims continue to influence peptide and cosmetic formulation strategies, underscoring the importance of ongoing innovation in stabilized peptide delivery systems.
End of report
More… ↓
⤷ Start Trial
|
